What's new — Irritable bowel syndrome¶
Generated 2026-11-01 from the publication dates of every paper cited in this condition's pages.
This page answers a different question from the curation log. The log says when we last edited a page; this says how recent the evidence on those pages is — so you can tell settled ground from a field that is actively moving, and jump straight to what has emerged lately.
How much of this condition's evidence is recent¶
| Published within | Cited papers |
|---|---|
| last week | 0 |
| last month | 0 |
| last 2 months | 13 |
| last 3 months | 15 |
| last 6 months | 24 |
| last year | 47 |
| older than a year | 334 |
Counts are cumulative: a paper from last week also counts inside "last month". Dates are PubMed publication or e-publication dates, so a paper may have appeared online before its journal issue.
Newest evidence first¶
The most recent cited papers, with the pages that use them.
| Published | Paper | Cited on |
|---|---|---|
| 2026-10-01 | Epidemiology of Irritable Bowel Syndrome Among Chilean Adults: Differences Across Healthcare Settings and Urban-Rural Populations — Neurogastroenterol Motil ([PMID 42928586](https://pubmed.ncbi.nlm.nih.gov/42928586/){target="_blank" rel="noopener"}) | epidemiology-and-burden |
| 2026-10-01 | A Genome-Wide Meta-Analysis of Functional Dyspepsia in 1,168,899 Individuals Implicates Immune Pathways in Disease Susceptibility — Neurogastroenterol Motil ([PMID 42897685](https://pubmed.ncbi.nlm.nih.gov/42897685/){target="_blank" rel="noopener"}) | overlap-with-functional-dyspepsia |
| 2026-10-01 | When Food Avoidance Meets Compatible Diagnostic Criteria: Avoidant/Restrictive Food Intake Disorder Features in Irritable Bowel Syndrome — Neurogastroenterol Motil ([PMID 42823900](https://pubmed.ncbi.nlm.nih.gov/42823900/){target="_blank" rel="noopener"}) | dietary-therapy, red-flags-and-safety-concerns |
| 2026-09-08 | No robust cortical morphometry differences and limited morphometry-phenotype associations in a UK Biobank irritable bowel syndrome phenotype — Neuroimage ([PMID 42710640](https://pubmed.ncbi.nlm.nih.gov/42710640/){target="_blank" rel="noopener"}) | brain-gut-axis-and-visceral-hypersensitivity |
| 2026-09-07 | Disordered Eating Behaviors Many Years After Education in a Low FODMAP Diet in Patients With Irritable Bowel Syndrome — JGH Open ([PMID 42712718](https://pubmed.ncbi.nlm.nih.gov/42712718/){target="_blank" rel="noopener"}) | dietary-therapy, red-flags-and-safety-concerns |
| 2026-09-07 | Rome V global epidemiology and validation survey: prevalence of disorders of gut-brain interaction and comparison with the Rome IV global epidemiology study — Gut ([PMID 42613194](https://pubmed.ncbi.nlm.nih.gov/42613194/){target="_blank" rel="noopener"}) | diagnosis-and-rome-criteria, epidemiology-and-burden, overlap-with-functional-dyspepsia, overview |
| 2026-09-04 | Mortality in Irritable Bowel Syndrome: The Tohoku Medical Megabank Project Community-based Cohort Study — J Neurogastroenterol Motil ([PMID 42702587](https://pubmed.ncbi.nlm.nih.gov/42702587/){target="_blank" rel="noopener"}) | epidemiology-and-burden |
| 2026-09-03 | Argentine consensus on the clinical utility of breath tests and small intestinal bacterial overgrowth management in patients with disorders of gut-brain interaction — Rev Gastroenterol Mex (Engl Ed) ([PMID 42816255](https://pubmed.ncbi.nlm.nih.gov/42816255/){target="_blank" rel="noopener"}) | guidelines |
| 2026-09-02 | Faecal microbiota transplantation in irritable bowel syndrome (REFIT2): a randomised, double-blind, placebo-controlled, phase 3 trial — Lancet ([PMID 42785338](https://pubmed.ncbi.nlm.nih.gov/42785338/){target="_blank" rel="noopener"}) | clinical-trials-landscape, microbiome |
| 2026-09-02 | Healthy donor faecal microbiota transplantation in irritable bowel syndrome: interpreting negative findings — Lancet ([PMID 42785337](https://pubmed.ncbi.nlm.nih.gov/42785337/){target="_blank" rel="noopener"}) | microbiome |
| 2026-09-01 | Biopsy-Confirmed Serofrequency of Celiac Disease among Patients with Disorders of Gut-Brain Interaction in Japan: A Multicenter Cross-Sectional Cohort Study — Inflamm Intest Dis ([PMID 42904019](https://pubmed.ncbi.nlm.nih.gov/42904019/){target="_blank" rel="noopener"}) | differential-diagnosis-and-exclusion |
| 2026-09-01 | Irritable bowel syndrome and suicide risk among adolescents: a prospective cohort study — Lancet Reg Health West Pac ([PMID 42787978](https://pubmed.ncbi.nlm.nih.gov/42787978/){target="_blank" rel="noopener"}) | red-flags-and-safety-concerns |
| 2026-09-01 | Comparison of demographic, clinical, and psychological characteristics among patients with irritable bowel syndrome meeting the Rome clinical, Rome V, and Rome IV criteria — Am J Gastroenterol ([PMID 42754968](https://pubmed.ncbi.nlm.nih.gov/42754968/){target="_blank" rel="noopener"}) | diagnosis-and-rome-criteria |
| 2026-08-09 | Systematic Review and Meta-Analysis: Plant-Based Therapy for Irritable Bowel Syndrome — Phytother Res ([PMID 42572206](https://pubmed.ncbi.nlm.nih.gov/42572206/){target="_blank" rel="noopener"}) | antispasmodics-and-peppermint |
| 2026-08-02 | Long-term microbiome and clinical effects of a microbiome-guided personalized diet versus low-FODMAP diet in irritable bowel syndrome: A 12-month follow-up randomized controlled trial — Gut Microbes ([PMID 42623122](https://pubmed.ncbi.nlm.nih.gov/42623122/){target="_blank" rel="noopener"}) | dietary-therapy |
| 2026-08-01 | Fiber Supplementation in Irritable Bowel Syndrome: A Systematic Review and Meta-Analysis of Randomized Controlled Trials — Gastroenterology ([PMID 42600900](https://pubmed.ncbi.nlm.nih.gov/42600900/){target="_blank" rel="noopener"}) | dietary-therapy |
| 2026-07-08 | Genetic dissection of stool frequency implicates vitamin B1 metabolism and other actionable pathways in the modulation of gut motility — Gut ([PMID 41558814](https://pubmed.ncbi.nlm.nih.gov/41558814/){target="_blank" rel="noopener"}) | brain-gut-axis-and-visceral-hypersensitivity |
| 2026-07-03 | Cost-of-Illness of Irritable Bowel Syndrome: A Systematic Review — J Gastroenterol Hepatol ([PMID 42538760](https://pubmed.ncbi.nlm.nih.gov/42538760/){target="_blank" rel="noopener"}) | epidemiology-and-burden, overview, quality-of-life-and-stigma |
| 2026-07-02 | The Rome V criteria for the diagnosis of irritable bowel syndrome in secondary care: a diagnostic accuracy study — Lancet Gastroenterol Hepatol ([PMID 42392123](https://pubmed.ncbi.nlm.nih.gov/42392123/){target="_blank" rel="noopener"}) | clinical-trials-landscape, diagnosis-and-rome-criteria, guidelines, overview |
| 2026-07-01 | Pathophysiology of irritable bowel syndrome — Lancet Gastroenterol Hepatol ([PMID 42462748](https://pubmed.ncbi.nlm.nih.gov/42462748/){target="_blank" rel="noopener"}) | brain-gut-axis-and-visceral-hypersensitivity, overlap-with-functional-dyspepsia, overview, post-infectious-ibs |
| 2026-06-09 | Physician-Patient Discordance in Bristol Stool Scale Classification and Overall IBS Burden Assessment — Am J Gastroenterol ([PMID 42289094](https://pubmed.ncbi.nlm.nih.gov/42289094/){target="_blank" rel="noopener"}) | diagnosis-and-rome-criteria |
| 2026-06-03 | Reassessing Small Intestinal Bacterial Overgrowth in Irritable Bowel Syndrome: A Comparative Study of Diagnostic Guidelines and Their Clinical Relevance — J Gastroenterol Hepatol ([PMID 42235989](https://pubmed.ncbi.nlm.nih.gov/42235989/){target="_blank" rel="noopener"}) | guidelines, rifaximin-and-the-sibo-question |
| 2026-06-01 | The Association Between Childhood Maltreatment and Adult Intestinal Disorders: A Three-Level Meta-Analysis — Trauma Violence Abuse ([PMID 42312593](https://pubmed.ncbi.nlm.nih.gov/42312593/){target="_blank" rel="noopener"}) | brain-gut-axis-and-visceral-hypersensitivity |
| 2026-06-01 | Targeted antibiotic and dietary approaches in managing small intestinal bacterial overgrowth across irritable bowel syndrome subtypes — Intern Emerg Med ([PMID 42310284](https://pubmed.ncbi.nlm.nih.gov/42310284/){target="_blank" rel="noopener"}) | rifaximin-and-the-sibo-question |
| 2026-05-01 | Disorders of Gut-Brain Interaction and the Rome V Process — Gastroenterology ([PMID 42031435](https://pubmed.ncbi.nlm.nih.gov/42031435/){target="_blank" rel="noopener"}) | diagnosis-and-rome-criteria, guidelines, overview |
| 2026-04-02 | Associations Between Irritable Bowel Syndrome, Depression, Anxiety, and Suicidal Ideation: a Partial Least Squares Path Analysis — Psychiatr Q ([PMID 42034841](https://pubmed.ncbi.nlm.nih.gov/42034841/){target="_blank" rel="noopener"}) | red-flags-and-safety-concerns |
| 2026-04-01 | Clinical and cost effectiveness of nurse led-structured management of diarrhoea predominant irritable bowel syndrome in primary care (Lincolnshire POACHER study); a randomised control trial — BMC Prim Care ([PMID 41922986](https://pubmed.ncbi.nlm.nih.gov/41922986/){target="_blank" rel="noopener"}) | quality-of-life-and-stigma |
| 2026-03-06 | Serological and faecal markers of irritable bowel syndrome: a systematic review and meta-analysis — EBioMedicine ([PMID 41793943](https://pubmed.ncbi.nlm.nih.gov/41793943/){target="_blank" rel="noopener"}) | brain-gut-axis-and-visceral-hypersensitivity, microbiome |
| 2026-03-02 | Mirtazapine for the treatment of irritable bowel syndrome: A systematic review — World J Methodol ([PMID 41809155](https://pubmed.ncbi.nlm.nih.gov/41809155/){target="_blank" rel="noopener"}) | gut-brain-neuromodulators |
| 2026-03-01 | Exploring Sex Differences in Irritable Bowel Syndrome Prevalence, Environmental Risk, and Comorbidities: A Population-Based Cohort Study of Veterans — Clin Transl Gastroenterol ([PMID 41489281](https://pubmed.ncbi.nlm.nih.gov/41489281/){target="_blank" rel="noopener"}) | brain-gut-axis-and-visceral-hypersensitivity, epidemiology-and-burden |
| 2026-02-02 | Strain-Specific Systematic Review with Meta-Analysis of Probiotics Efficacy in the Treatment of Irritable Bowel Syndrome — J Clin Med ([PMID 41682832](https://pubmed.ncbi.nlm.nih.gov/41682832/){target="_blank" rel="noopener"}) | microbiome |
| 2026-02-01 | Novel Symptom Subgroups in Patients With Irritable Bowel Syndrome Are Associated With Healthcare Utilisation in Secondary and Tertiary Care — Aliment Pharmacol Ther ([PMID 41714311](https://pubmed.ncbi.nlm.nih.gov/41714311/){target="_blank" rel="noopener"}) | diagnosis-and-rome-criteria |
| 2026-02-01 | Centrally Mediated Disorders of Gastrointestinal Pain — Gastroenterology ([PMID 41692277](https://pubmed.ncbi.nlm.nih.gov/41692277/){target="_blank" rel="noopener"}) | red-flags-and-safety-concerns |
| 2026-02-01 | Involvement of Eosinophil-Driven Intestinal Immune Activation in Different Irritable Bowel Syndrome Subtypes and in the Response to a FODMAP Lowering Diet: A Post Hoc Analysis of the Randomized Controlled DOMINO Trial — Gastroenterology ([PMID 41670574](https://pubmed.ncbi.nlm.nih.gov/41670574/){target="_blank" rel="noopener"}) | clinical-trials-landscape, dietary-therapy |
| 2026-01-08 | Face-to-Face Versus Digital, Telephone-Delivered, and Self-Help Cognitive Behavioral Therapy for Irritable Bowel Syndrome: Systematic Review and Bayesian Indirect Treatment Comparison Meta-Analysis — J Med Internet Res ([PMID 41505702](https://pubmed.ncbi.nlm.nih.gov/41505702/){target="_blank" rel="noopener"}) | psychological-therapy |
| 2026-01-08 | Functional Dyspepsia — N Engl J Med ([PMID 41499733](https://pubmed.ncbi.nlm.nih.gov/41499733/){target="_blank" rel="noopener"}) | overlap-with-functional-dyspepsia |
| 2026-01-02 | Peppermint Oil and Sweets in Pediatric Irritable Bowel Syndrome and Functional Abdominal Pain: A Randomized Trial — Clin Gastroenterol Hepatol ([PMID 41610933](https://pubmed.ncbi.nlm.nih.gov/41610933/){target="_blank" rel="noopener"}) | antispasmodics-and-peppermint |
| 2026-01-02 | Ethosuximide and Irritable Bowel Syndrome-Related Abdominal Pain: A Randomized Clinical Trial — JAMA Netw Open ([PMID 41505133](https://pubmed.ncbi.nlm.nih.gov/41505133/){target="_blank" rel="noopener"}) | gut-brain-neuromodulators |
| 2026-01-01 | Dose-Dependent Effect of the Histamine 1 Receptor Antagonist Ebastine in Patients With Non-Constipated Irritable Bowel Syndrome — Neurogastroenterol Motil ([PMID 41603723](https://pubmed.ncbi.nlm.nih.gov/41603723/){target="_blank" rel="noopener"}) | brain-gut-axis-and-visceral-hypersensitivity |
| 2026-01-01 | Mechanisms and pathophysiology leading to development of small intestinal microbial dysbiosis — Lancet Gastroenterol Hepatol ([PMID 41547360](https://pubmed.ncbi.nlm.nih.gov/41547360/){target="_blank" rel="noopener"}) | rifaximin-and-the-sibo-question |
| 2025-12-05 | The Six-Food Elimination Diet Improves Symptoms of Functional Dyspepsia — Clin Gastroenterol Hepatol ([PMID 41354185](https://pubmed.ncbi.nlm.nih.gov/41354185/){target="_blank" rel="noopener"}) | overlap-with-functional-dyspepsia |
| 2025-12-02 | Global Prevalence of Irritable Bowel Syndrome: An Updated Systematic Review and Meta-Analysis — Gastroenterology Res ([PMID 41488823](https://pubmed.ncbi.nlm.nih.gov/41488823/){target="_blank" rel="noopener"}) | epidemiology-and-burden |
| 2025-12-02 | Stability of Classification Systems for Irritable Bowel Syndrome — Aliment Pharmacol Ther ([PMID 41447016](https://pubmed.ncbi.nlm.nih.gov/41447016/){target="_blank" rel="noopener"}) | diagnosis-and-rome-criteria, epidemiology-and-burden, overview |
| 2025-12-02 | A study on the utility of inflammatory biomarkers in primary care irritable bowel syndrome: a sub analysis of the DOMINO randomized trial — BMC Gastroenterol ([PMID 41436948](https://pubmed.ncbi.nlm.nih.gov/41436948/){target="_blank" rel="noopener"}) | clinical-trials-landscape, dietary-therapy |
| 2025-12-01 | Postinfectious Syndromes and Long-Term Sequelae after Giardia Infections — Emerg Infect Dis ([PMID 41570191](https://pubmed.ncbi.nlm.nih.gov/41570191/){target="_blank" rel="noopener"}) | differential-diagnosis-and-exclusion, post-infectious-ibs |
| 2025-12-01 | A cellular basis for heightened gut sensitivity in females — Science ([PMID 41411420](https://pubmed.ncbi.nlm.nih.gov/41411420/){target="_blank" rel="noopener"}) | brain-gut-axis-and-visceral-hypersensitivity |
| 2025-11-02 | The Time-Dependent Association Between Irritable Bowel Syndrome and All-Cause and Cause-Specific Mortality in the NIH-AARP Cohort Study — Am J Gastroenterol ([PMID 41518229](https://pubmed.ncbi.nlm.nih.gov/41518229/){target="_blank" rel="noopener"}) | epidemiology-and-burden |
Trials — what has moved¶
68 registered trials are cited by this condition's pages. Registry records were re-checked live when this page was generated, so status, enrolment and results-posting below reflect ClinicalTrials.gov as of that date.
| Registry activity | Trials |
|---|---|
| trial records updated in the last week | 1 |
| trial records updated in the last month | 8 |
| trial records updated in the last 2 months | 16 |
| trial records updated in the last 3 months | 17 |
| trial records updated in the last 6 months | 21 |
| trial records updated in the last year | 30 |
Recently updated registrations¶
Posted efficacy and safety results¶
Trials whose sponsors have posted results to the registry. Adverse-event figures are participant counts summed across all arms as reported — read them against enrolment, and follow the registry link for the arm-by-arm breakdown that determines whether a signal is real.
| Results posted | Trial | Phase | N | Primary outcome | Serious AE | Other AE | Deaths |
|---|---|---|---|---|---|---|---|
| 2026-05-22 | Comparison of Rimegepant and Placebo for Pain in IBS | PHASE2 | 39 | Change in Abdominal Pain Scores | 0 | 6 | 0 |
| 2025-07-30 | Effects of Low FODMAP Diet on Colonic Epithelial Physiology in Diarrhe | NA | 48 | Lactulose Mannitol Excretion | 0 | 2 | 0 |
| 2023-03-28 | Efficacy and Safety of Rifaximin With NAC in IBS-D | PHASE1, PHASE2 | 45 | Change in Stool Form | 0 | 5 | 0 |
| 2022-05-04 | Efficacy and Safety of IBS Digital Behavioral Treatment | NA | 378 | Abdominal Pain Intensity Responder | 1 | 8 | 0 |
| 2021-09-05 | Efficacy and Safety of SYN-010 in IBS-C | PHASE2 | 59 | Change From Baseline in the Weekly Average Number of Completely Sponta | 1 | 23 | 0 |
| 2021-07-23 | Efficacy of Open Label Placebo in Children With FGIDs | NA | 31 | The Primary Outcome Measure Was Mean Daily Pain | 0 | 0 | 0 |
| 2020-04-13 | A 26-Week Study to Evaluate the Efficacy and Safety of Tenapanor in IB | PHASE3 | 593 | Percentage of Subjects With Overall Response for 6 Out of 12 Weeks | 12 | 58 | 0 |
| 2018-09-04 | Efficacy, Safety, and Tolerability of Eluxadoline in the Treatment of | PHASE3 | 1282 | Percentage of Participants Who Were Composite Responders Based on Impr | 68 | 220 | 0 |
| 2018-07-30 | Efficacy, Safety, and Tolerability of Eluxadoline in the Treatment of | PHASE3 | 1146 | Percentage of Participants Who Were Composite Responders Based on Impr | 31 | 263 | 0 |
| 2015-07-08 | Irritable Bowel Syndrome With Diarrhea (IBS-D) Rifaximin Re-Treatment | PHASE3 | 2583 | Repeat Treatment Responders | 36 | 341 | 0 |
| 2014-07-28 | Rifaximin 3 Times/Day (TID) for Non-Constipation Irritable Bowel Syndr | PHASE3 | 623 | Proportion of Subjects Who Had Adequate Relief of Global IBS Symptoms | 11 | 204 | 0 |
| 2014-07-28 | Rifaximin 3 Times/Day (TID) for Non-Constipation Irritable Bowel Syndr | PHASE3 | 637 | Proportion of Subjects Who Had Adequate Relief of Global IBS Symptoms | 14 | 180 | 0 |
34 of these trials are still recruiting or active — see the condition's clinical trials page for the full landscape.
Which pages rest on the newest evidence¶
🔥 marks a page citing three or more papers from the last year — the pages worth re-reading if you have been away.
| Page | Newest citation | In last year | Total citations |
|---|---|---|---|
| dietary-therapy | 2026-10-01 | 6 | 28 |
| epidemiology-and-burden | 2026-10-01 | 8 | 26 |
| overlap-with-functional-dyspepsia | 2026-10-01 | 5 | 27 |
| red-flags-and-safety-concerns | 2026-10-01 | 5 | 52 |
| brain-gut-axis-and-visceral-hypersensitivity | 2026-09-08 | 8 | 28 |
| diagnosis-and-rome-criteria | 2026-09-07 | 7 | 32 |
| overview | 2026-09-07 | 6 | 48 |
| guidelines | 2026-09-03 | 4 | 37 |
| clinical-trials-landscape | 2026-09-02 | 4 | 13 |
| microbiome | 2026-09-02 | 4 | 40 |
| differential-diagnosis-and-exclusion | 2026-09-01 | 2 | 23 |
| antispasmodics-and-peppermint | 2026-08-09 | 2 | 22 |
| quality-of-life-and-stigma | 2026-07-03 | 2 | 27 |
| post-infectious-ibs | 2026-07-01 | 2 | 26 |
| rifaximin-and-the-sibo-question | 2026-06-03 | 3 | 32 |
| gut-brain-neuromodulators | 2026-03-02 | 2 | 24 |
| psychological-therapy | 2026-01-08 | 1 | 21 |
| constipation-predominant-pharmacotherapy | 2025-10-01 | 0 | 24 |
| diarrhoea-predominant-pharmacotherapy | 2025-10-01 | 0 | 20 |
| placebo-response-and-trial-design | 2025-10-01 | 0 | 20 |
Recency is not quality: an old paper may be the definitive one, and a new paper may not replicate. Use this to find movement, not to rank evidence. See open questions for what remains unresolved, and the curation log for when these pages were last revised.